Pfizer breast cancer drug superior to chemotherapy in Phase III study

Dec 8 (Reuters) - Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday.